It's no secret that 3D cell culture is helping researchers develop more biologically relevant in vitro models for target discovery, and for testing the efficacy of anti-cancer drugs and therapeutic strategies. Many tumor cell lines readily form 3D multi-cellular tumor spheroids (MCTS), providing more physiologically relevant oxygen and nutrient diffusion gradients in which to assess anti-tumor drug efficacy. These models can reveal strikingly different phenotypes and response to drugs compared to the same cells grown in traditional 2D monolayer culture. Advanced 3D models seek to incorporate stromal cell constituents of the tumor microenvironment which play an important role in tumor growth, invasion, metastasis, and immune evasion. More complex in vitro tumor-stromal models such as these must both more accurately reflect this microenvironment, and provide the necessary compatibility with established cell-based assays and high-throughput workflows to successfully translate better biology into new, more effective therapies.
Since our founding in 2009, InSphero has been focused on only one thing: 3D cell culture. Over the past 7 years, we’ve grown from a supplier of innovative 3D culture technologies to become the industry’s only provider of comprehensive solutions to meet the needs of both simple and complex 3D tumor model development and testing. Leverage our 3D expertise, and get on the path to finding the cures.
Come see us at Booth #1912, or visit one of our posters to learn more about the use of advanced 3D tumor models for drug efficacy testing.
Grow your 3D model in our industry-leading GravityTRAP™ Ultra-low Attachment (ULA) Plate or GravityPLUS™ Hanging Drop System, comprising the only complete offering for production of simple and complex scaffold-free tumor spheroids. Learn which scaffold-free option is best for the model you want to build, place your order, and get started. You can even request a free sample plate from PerkinElmer, the exclusive distributor for InSphero GravityTRAP™ and GravityPLUS™ platforms. Our plates are designed to make the production, long-term culture, assay, and imaging of tumor spheroids as simple, reliable, and automation-compatible as possible. Want to move faster? Contract our 3D experts to develop a customized tumor or tumor-stromal model using our scaffold-free 3D culture platforms. Choose from over 100 established models using authenticated tumor cell lines from a variety of cancer types, alone or in co-culture with fibroblasts.
Either way, you benefit from fit-for-purpose technology, 3D-optimized media, and the consultation of our 3D experts.
Efficacy testing of anti-cancer drugs in 3D models requires a multi-faceted approach to monitoring growth via phenotypic and biochemical means. Our 3D experts can test your drugs, including small molecules, biologics, ADCs, RNAi, and more, in the 3D model or models of your choosing. Our 3D InSight™ Oncology Services utilize a menu of 3D-optimized protocols for common viability and mechanistic endpoints, many using the Cell3iMager for rapid, non-lytic, and label-free assessment of spheroid size. Standard services include:
- Efficacy testing – Determine the potency (IC50), efficacy (maximum response) and growth kinetics of your drug using size and ATP (viability) over a 10 day dosing regimen
- Combinatorial drug testing – Determine the potency (IC50), efficacy (maximum response) and growth kinetics of a combination of drugs using size and ATP (viability) over a 10 day dosing regimen
- Tumor relapse assay – Determine IC50 and IC20 for your drug, then assess tumor recurrence following single-dose vs. continuous treatment over 10 days
- Antibody penetration – Determine the penetration kinetics of your biological into a tumor spheroid to assess or optimize distribution efficiency
The quest for new cancer cures will require an integrated translational approach, utilizing novel, more biologically relevant 3D models for target discovery and validation, as well as integration of novel assay and imaging technologies to classify drug efficacy and synergism with existing treatment modalities.
The next cancer breakthroughs could already be within your grasp, but masked or deprioritized by other promising targets or leads identified in suboptimal in vitro models. Revealing them requires the willingness and resources to explore beyond the status quo of monolayer cell culture. We're here to be your guide and supply you with the tools, models, services, and 3D expertise you need to move forward with unfetttered confidence toward discovering cures and novel treatments.
Your 3D InSight™ Conference Planner
Visit our posters during AACR poster sessions or view them at your convenience during daily exhibit hours at our booth (#1912).
Sunday, April 17, 1-5 PM
Tumor Biology Poster Session, Section 33: Targeting the Microenvironment
Poster 30, Abstract 771 – Multi-parametric 3D tumor microtissue-based phenotypic compound classification
Presenting author: Madhu A. Lal, National Center for Advancing Translational Sciences (NCATS)
Short abstract: Here, we report on the development of homo- and heterotypic ovarian and pancreatic microtissue tumor models for screening up to 40 compounds selected from the NCATS Oncology focused library of small molecules. The goal of this study was to develop a high throughput compatible drug screening platform that could leverage the best of high throughput and high content screening assays to generate a pharmacological profile of activities that we hope will help better predict activity in vivo.
Novel Assays Poster Session, Section 18: Experimental and Molecular Therapeutics
Poster 9, Abstract 358 – Assessment of tumor recurrence with an in vitro 3D tumor microtissue model
Presenting author: Sumeer Dhal, InSphero AG
Short abstract: One of the most pressing problems in the treatment of cancer is tumor relapse. Although many tumors regress in response to neoadjuvant chemotherapy, residual tumor cells are detected in most cancer patients post-treatment. These residual tumor cells are thought to remain dormant for years before resuming growth, resulting in tumor recurrence. Considering that recurrent tumors are most often responsible for patient mortality, there exists an urgent need to study signaling pathways that drive tumor dormancy/recurrence. Current in vitro assays based on monolayer cultures do not provide the required time frame to study tumor recurrence. Here we present a novel in vitro tumor relapse assay method based on a 3-dimensional tumor microtissue model, to enable compound classification based on their efficiency to prevent tumor relapse.
Our 3D experts will demonstrate the functionality of the Cell3iMager Neo and teach you how to use our scaffold-free culture platforms.
A high-throughput bright field scanner for automated, label-free profiling of 3D spheroids
- Monday, April 18, 1-1:30 PM
- Tuesday, April 19, 1-1:30 PM
- Monday, April 18, 10-10:30 AM
- Tuesday, April 19, 10-10:30 AM